41
Views
37
CrossRef citations to date
0
Altmetric
Review

Recent developments in neuronal nicotinic acetylcholine receptor antagonists

, , &
Pages 1561-1581 | Published online: 25 Feb 2005

Bibliography

  • LLOYD K, WILLIAMS M: Neuronal nicotinic acetylcho-line receptors as novel drug targets. j Phannacol Exp. Ther. (2000) 292:461–467.
  • SARGENT PB: The diversity of neuronal nicotinic acetylcholine receptors. Ann. Rev. Neurosci. (1993) 16:403–443.
  • MCGEHEE DS, ROLE LW: Physiological diversity ofnicotinic acetylcholine receptors expressed by vertebra neurons. Ann. Rev. Physiol. (1995) 57:521–526.
  • WONNACOTT S: Presynaptic nicotinic acetylcholine receptors. Trends Neurosci. (1997) 20:92–98.
  • FRAZIER CJ, BUHLER AV, WEINER JL, DUNWIDDIE TV: Synaptic potential mediated via alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal interneurons. J. Neurosci. (1998) 18:8228–8235.
  • NODA M, TAKAHASHI H, TANABE T et al: Primary structures of beta- and delta-subunit precursors of Torpedo californica acetylcholine receptor deduced from cDNA sequences. Nature (1983) 301:251–255.
  • CHANGEUX JP, DEVILLERS-THIERY A, CHEMOUILLI P: Acetylcholine receptor: An allosteric protein. Science (1984) 225:1335–1345.
  • KARLIN A: Structure of nicotinic acetycholine receptors. CUIT. Opin. Neurobiol (1993) 3:299–309.
  • GALZI JL, CHANGEUX JP: Neuronal nicotinic receptors: molecular organization and regulations. Neuropharma-cology (1995) 34:563–582.
  • LEONARD R, LABARACA CG, CHARNET P, DAVIDSON N, LESTER HA: Evidence that the M2 membrane-spanning region lines the ion channel pore of the nicotinic receptor. Science (1988) 242:1578–1581.
  • CLAUDIO T, BALLIVET M, PATRICK J, HEINEMANN S: Nucleotide and deduced amino acid sequences of Torpedo californica acetylcholine receptor 7-subunit. Proc. Natl. Acad. Sci. USA (1983) 80:1111–1115.
  • CHANGEUX J, BERTRAND D, CORRINGER PJ et al.: Brain nicotinic receptors: structure and regulation, role in learning and reinforcement. Brain Res. Rev. (1998) 26:198–216.
  • COLQUHOUN L, PATRICK JW: Pharmacology of neuronal nicotinic acetylcholine receptor subtypes. Adv. Pharmacol. (1997) 39:191–220.
  • CACHELIN AB, RUST G: 13-Subunits co-determine thesensitivity of rat neuronal nicotinic receptors to antagonist. Pflugers Arch. Eur. J. PhysioL (1995) 429:449–451.
  • LE NOVERE N, CHANGEUX JP: Molecular evolution ofthe nicotinic acetylcholine receptor: an example of multigene family in excitable cells. j Mol. Evol. (1995) 40:155–172.
  • ORTELLS M, LUNT GG: Evolutionary history of theligand-gated ion-channel sup erfamily of receptors. Trends Neurosci. (1995) 18:121–127.
  • ANAND R, CONROY WG, SCHOEPFER R, WHITING P, LINDSTROM J: Neuron al nico tin ic acetylch olin e receptors expressed in Xenopus oocytes have a pentameric quaternary structure. J Biochem. (1991) 1 7:11192–11198.
  • COOPER E, COUTURIER S, BALIVET M: Pentamericstructure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor. Nature (1991) 350:235–238.
  • LUETJE CW, PATRICK J, SEGUELA P: Mapping of ligand binding sites of neuronal nicotinic acetylcholine receptors using chimeric alpha subunits. Mol. Pharmacol (1993) 44:657–666.
  • LUETJE C, PATRICK J: Both a- and 13-subunits contribute to the agonist sensitivity of neuronal nicotinic acetyl-choline receptors. J Neurosci. (1991) 11:837–845.
  • DENERIS ES, CONNOLLY J, ROGERS SW, DUVOISIN R: Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors. (1991) Trends Pharmac. ScL 12:34–40.
  • ROLE LW: Diversity in primary structure and functionof neuronal nicotinic acetycholine receptor channels. Curr. Opin. Neurobiol. (1992) 2:254–262.
  • ELGOYHEN EB, JOHNSON D, BOULTER J, VETTER D, HEINEMANN SF: An acetylcholine receptor with novel pharmacological properties expressed in rat cochlear hair cells. Cell (1994) 79:705–715.
  • COUTURIER S, BERTRAND D, MATTER JM et al: A neuronal nicotinic acetylcholine receptor subunit (a7) is developmentally regulated and forms a homo-oligomeric channel blocked by a-BTX. (1990) Neuron 5:847–856.
  • GERZANICH V, PENG X, WANG F et al: Comparative pharmacology of epibatidine: A potent agonist for neuronal nicotinic acetylcholine receptors. MoL Pharmacol. (1995) 48:774–782.
  • CONROY WG, VERNALLIS AB, BERG DK: The a5 gene product assembles with multiple acetylcholine receptor subunits to form distinctive receptor subtypes in brain. Neuron (1992) 9:679–691.
  • KEYSER KT, BRITTO LR, SCHOEPFER R et al.: Threesubtypes of alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors are expressed in chick retina. Neurosci. (1993) 13:442–454.
  • VERNALLIS AB, CONROY WG, BERG DK: Neurons assemble acetylcholine receptors with as many as three kinds of subunits while maintaining subunit segregation among receptor subtypes. Neuron (1993) 10 :451–464.
  • RAMIREZ-LATTORE JA, YU CR, QU X, PERIN F, KARLIN A,ROLE L: Functional contributions of a5 subunit to neuronal acetylcholine receptor channels. Nature (1996) 380:347–351.
  • FORSAYETH JR, KOBRIN E: Formation of oligomerscontaining the 133 and 134 subunits of the rat nicotinic receptor. J. Neurosci. (1997)17:1531–1538.
  • CAMPOS-CARO A, SMILLIE Fl, DOMINGUEZ DEL TORO E et al: Neuronal nicotinic acetylcholine receptors on bovine chromaffin cells: Cloning, expression and genomic organization of receptor subunits. J. Neurochem. (1997) 68:488–497.
  • GIROD R, CRABTREE G, ERNSTROM G etal.: Heteromericcomplexes of a5 and/or a7 subunits. Effects of calcium and potential role in nicotine-induced presynaptic facilitation. Ann. NY Acad. ScL (1999) 868:578–590.
  • POTH K, NETTER TJ, CUEVAS J et al: Heterogeneity ofnicotinic receptor class and subunit mRNA expression among individual parasympathetic neurons from rat in tr acardiac ganglia. J Neurosci. (1997) 17:586–596.
  • SCHOEPFER R, CONROY WG, WHITING P, GORE M, LINDSTROM J: Brain a-bungarotoxin binding protein, cDNAs and Mabs reveal subtypes of this branch of the ligand-gated ion channel gene sup er family . Neuron (1990) 5:35–48.
  • MULLE C, VIDAL C, BENOIT P, CHANGEUX JP: Existenceof different subtypes of nicotinic acetylcholine receptors in the rat habenulo-interpeduncular system. Neurosci. (1991) 11:2588–2597.
  • LUETJE CW, WADA K, ROGERS S et al: Neurotoxinsdistinguish between different neuronal nicotinic acetylcholine receptor subunit combinations. J. Neurochem. (1990b) 55:632–640.
  • CONNOLLY J, BOULTER J, HEINEMANN SF: a4-2132 andother nicotinic acetylcholine receptor subtypes as targets of psychoactive and addictive drugs. Br. J Pharmacol (1992) 105:657–666.
  • FIGL A, COHEN BN, QUICK MW, YANG XC, LESTER HA: Regions of beta4beta2 subunit chimera that contribute to the agonist selectivity of neuronal nicotinic receptors. FEBS Lett. (1992) 308:245–248.
  • PAPKE RL: The kinetic properties of neuronal nicotinic receptors: genetic basis and functional diversity. Prog. Neurobiol. (1993) 41:509–531.
  • STAFFORD GA, OSWALD RE, WETLAND GA: The beta subunit of neuronal nicotinic acetylcholine receptors is a determinant of the affinity for substance P Mol. Pharmacol (1993) 45:758–762.
  • CHAVEZ-NORIEGA LE, CRONA JH, WASHBURN MS, URRUTIA A, ELLIOTT KJ, JOHNSON EC: Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors ha2132, ha2134, ha3132, ha4132, ha4134 and ha7 expressed in Xenopus oocytes. j Pharmacol. Exp. Ther. (1997) 280:346–356.
  • HARVEY S, LUETJE CW: Determinants of competitiveantagonist sensitivity on neuronal nicotinic receptor 13subunits. j Neurosci. (1996) 16:3798–3806.
  • WHITING PJ, RUSHYA L, BARBARA JM, LINDSTROM JM:Structurally different neuronal nicotinic acetylcholine receptor subtypes purified and characterized using monoclonal antibodies. J Neurosci. (1987) 7:4005–4016.
  • WHITING PJ, LINDSTROM JM: Characterization ofbovine and human neuronal nicotinic acetylcholine receptors using monoclonal antibodies. J Neurosci. (1988) 8:3395–3404.
  • FLORES CM, ROGERS SW, PABREZA LA, WOLFE BB, KELLAR KJ: A subtype of nicotinic cholinergic receptor in rat brain is composed of 04 and 132 subunits and is up-regulated by chronic nicotine treatment. Mol. Pharmacol. (1992) 41:31–37.
  • WADA E, WADA K, BOULTER J, DENERIS E etal.: Distribu-tion of alpha2, alpha3, alpha4 and beta2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: A hybridization histochemical study in the rat. J Comp. Neurol. (1989) 284:314–335.
  • CLARKE PBS, SCHWARTZ RD, PAUL SM, PERT CB, PERT A:Nicotinic binding in rat brain: Autoradiographic comparison of [31-flacetylcholine and [125I]-alpha bungarotoxin. j Neurosci. (1985) 5:1307–1315.
  • MARKS MJ, STITZEL JA, ROMM E, WEHNER JM, COLLINS AC: Nicotine binding sites in rat and mouse brain: comparison of acetylcholine, nicotine and alpha-bun gar o to x in . Mol. Pharmacol. (1986) 30:427–436.
  • PICCIOTTO MR, ZOLI M, RIMONDINI R et al: Acetylcho-line receptors containing the 132 subunit are involved in the reinforcing properties of nicotine. Nature (1998) 391:173–177.
  • PICCIOTTO MR, ZOLI M, LENA C et al.: Abnormalavoidance learning in mice lacking functional high affinity nicotinic receptors in the brain. Nature (1995) 376:65–67.
  • ZOLI M, LENA C, PICCIOTTO MR, CHANGEUX JP: Identifi-cation of four classes of brain nicotinic receptors using beta-2 mutant mice. J. Neurosci. (1998) 18:4461–4472.
  • GARCIA-GUZMAN M, SALA M, SALA F et al.:a-Bungarotoxin-sensitive nicotinic receptors on bovine chromaffin cells: Molecular cloning, functional expression and alternative splicing of the a7 subunit. Eur. j Neurosci. (1995) 7:647–655.
  • DOMINGUEZ DEL TORO E, JUIZ JM, SMILLIE Fl,LINDSTROM J, CRIADO M: Expression of a7 neuronal nicotinic receptors during postnatal development of the rat cerebellum. Dev. Brain Res. (1997) 98:125–133.
  • ORR-URTREGER A, GOLDNER FM, SAEKI M: Mice deficient in the a7 neuronal nicotinic acetylcholine receptor lack a-bungarotoxin binding sites and fast nicotinic currents. J Neurosci. (1997) 17:9165–9171.
  • LIPPIELLO P: Properties of putative nicotine receptorsidentified on cultured cortical neurons. Prog. Brain Res. (1989) 79:129–135.
  • RAKHILIN S, DRIDEL RC, SAGHER D, MCGEHEE DS, VALLEJO Y, GREEN WN: a-Bungarotoxin receptors contain a7 subunits in two different disulfide-bonded conformations. J Cell Biol. (1999) 146:203–218.
  • SCHULZ DW, ZIGMOND RE: Neuronal bungarotoxin blocks the nicotinic stimulation of dopamine release from rat striatum. Neurosci. Lett. (1989) 98:310–316.
  • GRADY SR, MARKS MJ, WONNACOTT S, COLLINS AC: Characterization of nicotinic receptor-mediated [3H]dopamine release from synaptosome prepared from mouse striatum. J Neurochem. (1992) 59:848–856.
  • CARTIER GE, YOSHIKAMI D, GRAY WR, LUO S, OLIVERA BM, MCINTOSH JM: A new a-conotoxin which targets a3132 nicotinic acetylcholine receptors. J Biol. Chem. (1996) 271:7522–7528.
  • KAISER S, WONNACOTT S: Alpha-bungarotoxin sensitive nicotinic receptors indirectly modulate [3H]dopamine release in rat striatal slices via glutamate release. Mol. Pharmacol. (2000) 58:312–318.
  • CROOKS PA, RAVARD A, WILKINS LH, TENG LH, BUXTON ST, DWOSKIN LP: Inhibition of nicotine-evoked [31-1]dop amine release by pyridino N-substituted nicotine analogues: a new class of nicotinic antago-nist. Drug Dev. Res. (1995) 36:91–102.
  • KULAK JM, NGUYEN TA, OLIVERA BM, MCINTOSH JM: a-Conotoxin MII blocks nicotine-stimulated dopamine release in rat striatal synaptosomes. Neurosci. (1997) 17:5263–5270.
  • RAPIER C, LUNT GC, WONNACOTT S: Nicotine modula-tion of [3H]dopamine release from striatal synapto-somes: Pharmacological characterization. J Neurochem. (1990) 54:937–945.
  • SHARPLES CG, KAISER S, SOLIAKOV L et al.: UB-165: anovel nicotinic agonist with subtype selectivity implicates the alpha4beta2*subtype in the modulation of dopamine release from rat striatal synaptosomes. Neurosci. (2000) 20:2783–2791.
  • DENERIS ES, BOULTER J, SWANSON LW, PATRICK J, HEINEMANN S: 133: Anew member of nicotinic acetyl-choline receptor gene family is expressed in brain. J Biol. Chem. (1989) 264:6268–6272.
  • DINELEY-MILLER K, PATRICK J: Gene transcripts fromthe nicotinic acetylcholine receptor subunit, beta4, are distributed in multiple areas of the rat central nervous system. Mol. Brain Res. (1992) 16:339–344.
  • CHARPANTIER E, BARNEOUD P, MOSER P, BESNARD F, SGARD F: Nicotinic acetylcholine subunit mRNA expression in dopaminergic neurons of the rat substantial nigra and ventral tegrnental area. NeuroRe-port (1998) 9:3097–3101.
  • ARROYO-JIMENEZ MM, BORUGEOIS JP, MARUBIO LM et Ultrastructure localization of the alpha4 subunit of the neuronal acetylcholine nicotinic receptor in the rat substantia nigra. j Neurosci. (1999) 19:6475–6487.
  • LENOVERE N, ZOLI M, CHANGEUX JP: Neuronal nicotinic receptor a6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur. j Neurosci. (1996) 8:2428–2439.
  • GOLDNER FM, DINELEY KT, PATRICK JW: Irnmunohisto-chemical localization of the nicotinic acetylcholine receptor subunit a6 to dopaminergic neurons in the substantia nigra and ventral tegrnental area. NeuroRe-port (1997) 8:2739–2742.
  • GOPALAKRISHNAN M, MONTIGGIA LM, ANDERSON DJ et al.: Stable expression, pharmacologic properties and regulation of human nicotinic acetylcholine a4132 receptor. J. Pharmacol. Exp. Ther. (1996) 276:289–297.
  • QUIK M, CHOREMIS J, KOMOURIAN J, LUKAS RJ, PUCHACZ E: Similarity between rat brain nicotinic a-bungarotoxin receptors and stably expressed a-bungarotoxin binding sites. J. Neurochem. (1996) 67:145–154.
  • GOPALAKRISHNAN M, BUISSON B, TOUMA E et al: Stable expression and pharmacological properties of the human a7 nicotinic acetylcholine receptor. Eur. Pharmacol. (1995) 290:237–246.
  • WHITEAKER P, DAVIES AR, MARKS MJ et al.: An autora-diographic study of the distribution of binding sites for the novel a7-selective nicotinic radioligand [3H]-methyllycaconitine in the mouse brain. Eur. Neurosci. (1999) 11:2689–2696.
  • DAVIES A, HARDICK DJ, BLAGBROUGH IS, POTTER By, WOLSTENHOLME AJ, WONNACOTT S: Characterisation of the binding of [311]methyllycaconitine: a new radioligand for labelling a7-typ e neuronal nicotinic acetylcholine receptors. Neuropharmacology (1999) 38:679–690.
  • MARKS MJ, SMITH KW, COLLINS AC: Differential agonistinhibition identifies multiple epibatidine binding sites in mouse brain. J. Pharmacol. Exp. Ther. (1998) 285:377–386.
  • WHITEAKER P, MCINTOSH JM, LUO S, COLLINS AC, MARKS MJ: 125I-alpha-conatoxin MII identifies a novel nicotinic acetylcholine receptor population in mouse brain. Mol. Pharmacol (2000) 57:913–925.
  • MARKS MJ, FARNHAM DA, GRADY SR, COLLINS AC: Nicotinic receptor function determined by stimulation of rubidium efflux from mouse brain synap tosomes. Pharmacol. Exp. Ther. (1993) 264:542–552.
  • PAPKE R, THINSCHMIDT JS: The correction of a7nicotinic acetylcholine receptor concentration-response relationships in Xenopus oocytes. Neurosci. Lett. (1998) 256:163–166.
  • PAPKE R, MEYER E, NUTTER T, UTESHEV VV: a7 receptor-selective agonists and modes of a7 receptor activation [In Process Citation]. Eur.J. Pharmacol. (2000) 393:179–195.
  • SEGUELA P, WADICHE J, DINELEY-MILLER K, DANI JA, PATRICK JW: Molecular cloning, functional, properties and distribution of rat brain a7: a nicotinic cation channel highly permeable to calcium. j Neurosci. (1993) 13:596–604.
  • LUKAS R: Expression of ganglia-type nicotinic acetyl-choline receptors and nicotinic ligand binding sites by cells of the IMR-32 human neuroblastoma clonal line. J. Pharmacol. Exp. Ther. (1993) 265:294–302.
  • DONNELLY-ROBERTS D, PUTTFARCKEN PS, KUNTZWEILER TA et al: ABT-594 KR)-5-(2-azetidinyl methoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization. J Pharmacol Exp. Ther. (1998) 285:777–786.
  • GOTTI C, FORNASARI D, CLEMENTI F: Human neuronal nicotinic receptors. Prog. Neurobiol (1997) 53:199–237.
  • CLARKE PBS, CHAUDIEU I, EL-BIZRI H et al: The pharma-cology of the nicotinic antagonist, chlorisondamine, investigated in rat brain and autonomic ganglion. Br. J Pharmacol. (1994) 111:397–405.
  • LINGLE C: Blockade of cholinergic channels by chlori-sondamine on a crustacean muscle. J Physiol (London) (1983) 339:395–417.
  • VARANDA WA, ARACAVA Y, SHERBY SM, VAN METER WG, ELDEFRAWI ME, ALBUQUERQUE EX: The acetylcho-line receptor of the neuromuscular junction recognizes mecamylamine as a noncompetitive antagonist. Mol. Pharmacol. (1985) 28:128–137.
  • BANERJEE S, PUNZI JS, KREILICK K, ABOOD LG: [311]Mecamylamine binding to rat brain membranes. Biochem. Pharmacol. (1990) 40:2105–2110.
  • MARTIN TJ, SUCHOCKI J, MAY EL, MARTIN BR: Pharma-cological evaluation of the antagonism of nicotine's central effects by mecamylamine and pempidine. Pharmacol. Exp. Ther. (1990) 254:45–51.
  • LOIACONO R, STEPHENSON J, STEVENSON J, MITCHELSON F: Multiple binding sites for nicotine receptor antagonists in inhibiting [3H](-)-nicotine binding in rat cortex. Neuropharmacology (1993) 32:847–853.
  • PENG O, GERZANICH V, ANAND R, WHITING PJ, LINDSTROM J: Nicotine-induced increase in the neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. Mol. Pharmacol (1994) 46:523–530.
  • O'DELL TJ, CHRISTENSEN BN: Mecamylamine is aselective non-competitive antagonist of N-methyl-D-aspartate and aspartate-induced currents in horizontal cells dissociated from the catfish retina. Neurosci. Lett. (1988) 94:93–98.
  • REYNOLDS IJ, MILLER RJ: rHilVIK801 binding to the N-methyl-D-aspartate receptor reveals drug interac-tions with zinc and magnesium binding sites. J. Pharmacol. Exp. Ther. (1988) 2 47 (3) :1025–1031.
  • SNELL LD, JOHNSON KM: Effects of nicotinic agonists and antagonists on N-methyl-D-aspartate-induced 3H-noradrenaline release and 3H41-(2-thienyl) cyclohexyli-piperidine) binding in rat hippocampus. Synapse (1989) 3:129–135.
  • COURT JA, PIGGOTT MA, PERRY EK: Nicotine reduces the binding of [31I]MK-801 to brain membranes, but not via the stimulation of high-affinity nicotinic receptors. Brain Res. (1990) 524:319–321.
  • REAVILL C, JENNER P, KUMAR R, STOLERMAN IP: High affinity binding of [311](-)nicotine to rat brain membranes and its inhibition by analogues of nicotine. Neuropharmacol (1988) 27:235–241.
  • DOISY X, BLAGBROUGH IS, WONNACOTT S, POTTER BV: Design, synthesis and biological evaluation of substi-tuted benzoate analogs of the selective nicotinic acetyl-choline receptor antagonist, methyllycaconitine. Pharm. Pharmacol. Comm. (1998) 4:313–317.
  • WHITEAKER P, DAVIES AR, MARKS MJ et al.: A autoradio-graphic study of the distribution of binding sites for the novel the novel alpha7 -selective nicotinic radioligand [3H]-methyllycaconitine in the mouse brain. Eur.J. Neurosci. (1999) 11:2689–2696.
  • BERGMEIER S, LAPINSKY DJ, FREE RB, MCKAY DB: RingE analogs of methyllycaconitine (MLA) as novel nicotinic antagonists. Bioorg. Med. Chem. Lett. (1999) 9:2263–2266.
  • HOLLADAY M, DART MJ, LYNCH JK: Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J Med. Chem. (1997) 40:4169–4194.
  • MCINTOSH J, SANTOS AD, OLIVERA BM: Conus peptides targeted to specific nicotinic acetylcholine receptor subtypes. Ann. Rev. Biochem. (1999) 68:59–88.
  • DWOSKIN LP, WILKINS LH, PAULY JR, CROOKS PA: Development of a novel class of subtype-selective nicotinic receptor antagonist: Pyridine-N-substituted nicotine analogs. Ann. NY Acad. Sci. (1999) 868:617–619.
  • DWOSKIN LP, TENG LH, BUXTON ST et al: Minor alkaloids of tobacco release [311]dopamine from superfused rat striatal slices. Eur. j Pharmacol (1995) 276:195–199.
  • KEM WR, MAHNIR VM, LIN V: Interaction of DMXBA (GTS-21), a cognition enhancing compound, with cholinergic receptors. Soc. Neurosci. Abstr. (1994) 20:1134–1467.
  • DECKER MW, BRIONI JD, BANNON AW, ARNERIC SP: Diversity of neuronal nicotinic acetylcholine receptors: Lessons from behavior and implications for CNS therapeutics. Life Sci. (1995) 56:545–570.
  • CORRIGALL WA, FRANKLIN KBJ, COEN KM, CLARKE PBS: The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharma-cologia (1992) 107:285–289.
  • CORRIGALL WA, COEN KM, ADAMSON KL: Self-administered nicotine activates the mesolimbic do p aminergic system through the ventral tegrn en tal area. Brain Res. (1994) 653:278–284.
  • DONNY EC, CAGGIULA AR, KNOF S, BROWN C: Nicotine self-administration in rats. Psychopharmacology (1995) 122:390–394.
  • DONNY EC, CAGGIULA AR, MIELKE MM, JACOBS KS, ROSE C, SVED AF: Acquision of nicotine self- admini-stration in rats: the effects of dose, feeding schedule and drug contingency. Psychopharmacology (1998) 136:83–90.
  • BARDO MT, GREEN TA, CROOKS PA, DWOSKIN LP: Nornicotine is self-administered intravenously by rats. Psychopharmacology (1999) 146:290–296.
  • RASMUSSEN T, SWEDBERG MDB: Reinforcing effects of nicotinic compounds: intravenous self- administra-tion in drug naive mice. Pharmacol Biochem. Behav. (1998) 60:567–573.
  • REAVILL C, WALTHER B, STOLERMAN IP, TESTA B: Behavioral and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology (1990) 2 9:619–624.
  • CLARKE PBS, KUMAR R: The effect of nicotine on locomotor activity in non-tolerant and tolerant rats. Br. J. Pharmacol. (1983) 78:329–337.
  • FUDALA PJ, TEOH KW, IWAMOTO ET: Pharmacological characterization of nicotine-induced place prefer-ence. Pharmacol Biochem. Behav. (1985) 22:237–241.
  • SHOIAB M, STOLERMAN IP, KUMAR RC: Nicotine induced place preference following prior nicotine exposure in rats. Psychopharmacology (1 9 9 4) 113:445–452.
  • STOLERMAN IP, GARCHA HS, MIRZA NR: Dissociation between the locomotor stimulant and depressant effects ofnicotinic agonists in rats. Psychopharmacology (1995) 117:430–437.
  • TENG LH, CROOKS PA, SONSALLA PK, DWOSKIN LP: Lobeline and nicotine evoke rilioverflow from rat striatal slices preloaded with riliclopamine: differen-tial inhibition of synaptosomal and vesicular [3H]dopamine uptake. J. Pharmacol. Exp. Ther. (1997) 80:1432–1444.
  • MILLER DK, CROOKS PA, DWOSKIN LP: Lobeline inhibits nicotine-evoked rilidop amine overflow from rat striatal slices and nicotine-evoked 86Rb+ efflux from thalamic synaptosomes. Neuropharmacology (2000): [In Press].
  • CALDWELL WS: Structure-activity study of RJR-2429 analogs: development of selective ligands for nicotinic acetylcholine receptors. AAPS Pharm. ScL Suppl. (1999) 1 (4):S399, Abstract 3124.
  • LUO S, NGUYEN TA, CARTIER GE, OLIVERA BM, YOSHIKAMI D, MCINTOSH JM: Single-residue alteration in a-conotoxin PnIA switches its NAChR subtype selectivity. Biochemistry (1999) 38:14542–14548.
  • LOUGHNAN M, BOND T, ATKINS A et al: a-Conotoxin EpI, a novel sulfated peptide from Conus episcopatus that selectively targets neuronal nicotinic acetycho-line receptors. J. Biol. Chem. (1998) 273:15667–15674.
  • HOGG RC, MIRANDA LP, CRAIK DJ, LEWIS RJ, ALEWOOD PF, ADAMS DJ: Single amino acid substitutions in a-Conotoxin PnIA shift selectivity for subtypes of the mammalian neuronal nicotinic acetylcholine receptor. j Biol. Chem. (1999) 274:36559–36564.
  • LIN N, MEYER MD: Recent developments in neuronal nicotinic acetylcholine receptor modulators. Exp. Opin. Ther. Patents (1998) 8:991–1015.
  • SCHMITT JD, BENCHERIF M: Targeting nicotinic acetyl-choline receptors: Advances in molecular design and therapies. Ann. Rep. Med. Chem. (2000) 35 :[In Press].
  • SCHMITT JD: Exploring the nature of molecular recognition in nicotinic acetylcholine receptors. Current Med. Chem. (2000) [In Press].
  • GLENNON RA, DUKAT M: Nicotinic cholinergic receptor pharmacophores. In: Neuronal Nicotinic Receptors. Arneric SP, Brioni JD (Eds.), Wiley-Liss, NY, USA (1999):271–284.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.